Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib First-Line in Advanced NSCLC
NCT00615758Phase 2Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Oct 2006
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Hellenic Oncology Research Group. Primary endpoint: Overall Response Rate. Started Oct 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00615758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00615758.